• Procept BioRobotics posted Q2 revenue of $94.5 million, up 19% from the prior-year period; GAAP net loss widened to $26.9 million.
• Gross margin edged up 1 percentage point to 66%, due to higher U.S. system and consumable pricing and a $2.9 million tariff refund.
• U.S. procedures climbed about 21% to over 13,100; the company delivered 65 U.S. HYDROS systems, including 14 replacements.
• Average selling price for new U.S. HYDROS systems was about $495,000; handpiece ASP rose 11% to about $3,550.
• Maintained full-year revenue guidance of $390 million-$410 million; lifted U.S. procedure outlook to 54,000-56,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.